Testing effectiveness (Phase 2)Ended earlyNCT02992964
What this trial is testing
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
Who this might be right for
Refractory or Recurrent Hypermutated MalignanciesBiallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
The Hospital for Sick Children 11